SUMMARY Thirteen patients developed syncope and a prolonged QTc interval while taking therapeutic doses of sotalol. Polymorphous ventricular tachycardia was observed in 12 patients, and criteria typical of torsade de pointes were present in 10. In 12 patients sotalol had been given with hydrochlorothiazide in a combined preparation, Sotazide, but with inadequate or no potassium supplementation. Serum potassium concentrations were reduced in eight patients. Four patients were taking other drugs known to prolong the QT interval, including disopyramide (three patients) and tricyclic antidepressants (two patients). The QT interval returned to normal in all patients after withdrawal of the drugs and correction of the hypokalaemia. Thus even in low dosage sotalol may be hazardous in the presence of hypokalaemia or when combined with drugs that also prolong the QT interval. The use of sotalol concurrently with potassium losing diuretics, such as the combined preparation Sotazide, may expose the patient to unnecessary risk and should be avoided x;nless the class III antiarrhythmic action of this unique beta adrenoreceptor blocking agent is also required.
Drugs that prolong the QT interval may cause life threatening ventricular arrhythmias, particularly of the torsade de pointes' 2 or polymorphous ventricular tachycardial variety. These have been reported in association with several of the class I antiarrhythmic drugs, such as quinidine,4 procainamide,' I and disopyramide. 6 I Amiodarone, an antiarrhythmic drug that prolongs the-QT interval by virtue of its class III properties, has also been associated with torsade de pointes.'
Over the past few years, interest has been shown in the class III antiarrhythmic action of the beta adrenergic blocking agent sotalol.1'" Evidence is accumulating that sotalol is a more effective antiarrhythmic agent than other beta blockers9" 12 and this has been attributed to its class III activity. Several reports,'2-" however, have suggested that like other antiarrhythmic agents it may be arrhythmogenic. Elonen Accepted for publication 11 October 1983 recorded in five of the six and correlated with the prolongation of the QT interval and the serum sotalol concentration. Ventricular tachyarrhythmias associated with a prolonged QT interval have also been reported in three patients taking large but therapeutic doses of sotalol; '3 14 in one of the three the tachycardia was typical of torsade de pointes. '4 The present study reports 13 patients who developed a prolonged QT interval and syncope after taking relatively small therapeutic doses of sotalol.
Patients and methods

CLINICAL DATA
Between 1979 and 1983 13 patients, all but one of whom were female, developed syncope and a prolonged QT interval while taking sotalol (Table) . The daily dose ranged from 80 to 480 mg. Twelve were being treated for hypertension (including one with frequent ventricular extrasystoles), and one (case 7) was taking sotalol and other agents for frequent ventricular extrasystoles associated with ischaemic heart disease. All but one of the 13 patients were taking the combined preparation Sotazide (sotalol hydrochloride 160 mg, hydrochlorothiazide 25 (Table) . Ventricular arrhythmnias Polymorphous ventricular tachycardia was recorded on the electrocardiogram in 11I patients (Table) . Ventricular tachycardia was observed on the monitor screen but was not recorded in another (case 12), whereas in the remaining patient (case 10), the 80 year old woman with a QTc of 0-76 s and a constant bigeminal rhythm (Fig. 1) , the probability that a ventricular tachyarrhythmia was responsible for her syncope was never confirmed. attack and was found to have ventricular bigeminy (Fig. 3a) with frequent short runs of a polymorphous ventricular tachycardia ( Fig. 3b and d) . The QTc interval measured 0-64 s and the serum potassium concentration was 3.8 mmol/l. Treatment with Sotazide was stopped, and he was given potassium supplements. Within 24 hours the QTc interval was 0-44 s (Fig. 3c ) and all ventricular arrhythmias had ceased.
Case 9-A 38 year old woman had been treated for hypertension with hydralazine, methyldopa, and cyclopenthiazide (Navidrex) two tablets daily for four months. Because of inadequate control, the latter two drugs were stopped and replaced by Sotazide in a dose of two tablets daily. Three days later, after a total of six tablets of Sotazide, she had syncope associated with palpitations and sweating. On admission the QTc interval was 0-62 s, and several self limiting runs of torsade de pointes were recorded (Fig. 4) 
Sotalol and torsade de pointes Discussion
A polymorphous ventricular tachycardia was observed in 12 of our 13 patients. Features classical of torsade de pointes2 318were identified in 10 of the 11 patients who had electrocardiographic recordings of the ventricular tachycardia. In all 11 patients the arrhythmia was initiated by a ventricular extrasystole occurring on the preceding T wave. In only one patient (case 10) was a ventricular tachycardia neither recorded nor observed on a monitor. Nevertheless it is highly likely that a ventricular tachyarrhythmia was responsible for her syncope since she had ventricular bigeminy with the R on T phenomenon and a notably prolonged QT interval. Furthermore, the syncope did not recur after withdrawal of the drugs.
In 1970 Singh and Vaughan Williams showed that sotalol (MJ 1999) prolonged the repolarisation phase of the ventricular action potential in isolated cat papillary muscle and that it prolonged the QTc interval of the electrocardiogram in anaesthetised guinea pigs.'0 Several workers have shown that these class III antiarrhythmic effects also occur in man,9 11 19 and this has raised the probability that sotalol has antiarrhythmic properties distinct from those of other beta blocking agents. Prolongation Definite hypokalaemia was detected in eight of our 13 patients, although this was mild (serum potassium concentration 3-3 5 mmol/l) in five. Another three had serum potassium concentrations below 4 mmol/l, and thus only two patients (cases 3 and 12) had a serum potassium concentration above this value. Hypokalae-161 mia alone could not have been responsible for the ventricular arrhythmias because the QT intervals were very prolonged, a feature that certainly cannot be explained on that basis. None the less, hypokalaemia does appear to have been an important predisposing factor. In three of the eight patients (cases 4, 7, and 10) with definite hypokalaemia, there were additional factors which may have contributed to the prolonged QT interval and the ventricular extrasystoles. Two patients (cases 7 and 10) were taking disopyramide, a drug known to predispose to torsade de pointes. 6 7 Disopyramide had been given concomitantly with Sotazide in one (case 7) of these two. The other patient (case 10) was also taking imipramine 50 mg daily, which is too small a dose to play a primary role but which may well have contributed to the prolonged QT interval.24 The third patient (case 4) had been taking amitriptyline and imipramine for nine months. In all three patients syncope occurred within 48 hours of taking Sotazide.
Of the five patients (cases 1, 3, 5, 8, and 12) who did not have serum potassium concentrations below 3 5 mmol/l, there were four (cases 1, 3, 5, and 8) in whom no factor other than Sotazide could be implicated. One of these patients (case 3) had had a renal transplantation two days before taking Sotazide and probably had impaired renal excretion with resulting high serum concentrations of sotalol. In support of this is the fact that the QTc interval took three days to return to normal, although she had taken a total of only five tablets of Sotazide. The second patient (case 1) without definite hypokalaemia (serum potassium concentration 3*6 mmol/1) developed syncope within two hours of taking one tablet of Sotazide. Two others (cases 5 and 8) had serum potassium concentrations of 3 8 mmol/l after taking Sotazide for five weeks and one year. An arrhythmogenic role of a low myocardial potassium concentration in these latter three patients with normal, albeit relatively low, serum potassium concentrations cannot be excluded since the relation between myocardial potassium, total body potassium, and serum potassium concentrations remains uncertain.25 The fifth patient (case 12) had a serum potassium concentration of 4'2 mmol/l which is the highest value in our series. She had been taking Sotazide two tablets daily for a year but had been given disopyramide 300 mg daily two weeks before her syncopal attack. 162 refractory period of cardiac muscle.27 From the data currently available, some prolongation of the QT interval will occur in many patients taking sotalol.9 [20] [21] [22] The risk of their developing torsade de pointes is unknown and requires further investigation. There may be predisposing "sensitivity" factors that render sotalol particularly dangerous in individual patients but which require clarification. From our experience, we conclude that hypokalaemia, even when mild, is one such factor. Concomitant treatment with disopyramide is probably another, and high serum sotalol concentrations"3 14 are a third. The prescribing of sotalol, when other beta blockers are equally suitable, together with a thiazide diuretic constitutes an unjustifiable risk in the long term treatment of any condition-most notably hypertension-in which hypokalaemia commonly ensues as a consequence of the diuretic therapy. We, therefore, see little justification for the use of the combined preparation, Sotazide.
It is our present policy to confine the use of sotalol to those situations in which both its class III antiarrhythmic and beta receptor blocking effects are required. We have had favourable experience with the drug in the treatment of atrial and ventricular arrhythmias. Because of its class III property sotalol may be superior to other beta blockers in the long term therapy of hypertrophic cardiomyopathy and symptomatic primary mitral valve prolapse, but these observations require confirmation. Similarly, and despite the findings of Julian and co-workers that sotalol failed to reduce the incidence of sudden death as opposed to reinfarction during the first year after myocardial infarction,28 this unique beta receptor blocking agent may still prove advantageous in treating selected cases of ischaemic heart disease. Under all circumstances, hypokalaemia must be avoided, and thus patients should be advised to stop taking sotalol should-for example-an attack of acute gastroenteritis develop. Sotalol should also be given extremely cautiously in conjunction with other drugs known to prolong the QT interval such as class I antiarrhythmic agents, phenothiazines, and tricycic antidepressants. We thank Dr J Veriawa, Coronation Hospital, for bringing the first case in this series to our attention.
